Crassula Pharmaceuticals Launches Relixib, Etoricoxib 120mg, in Honduras
Relixib 120mg Tablet
Tegucigalpa, Honduras – Crassula Honduras, a leading pharmaceutical manufacturer renowned for its commitment to quality, is excited to announce the introduction of Relixib, an etoricoxib 120mg tablet, to the Honduran market. This new addition to Crassula’s portfolio reinforces the company’s dedication to providing advanced healthcare solutions and addressing the needs of patients suffering from chronic pain and inflammation.
Etoricoxib, the active ingredient in Relixib, belongs to a class of medications known as selective COX-2 inhibitors, offering targeted relief from pain and swelling associated with various arthritic conditions, including osteoarthritis, rheumatoid arthritis, and gout. The 120mg dosage has been carefully selected to optimise efficacy while minimizing potential side effects, ensuring a better quality of life for patients.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance